ArticleFrontiers in oncology2023

Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine.

Giuseppe A Palumbo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.